Treatment
Venetoclax clinical trials
We’re tracking 282 recruiting studies that include Venetoclax, each written for real people, not researchers, below.
Recruiting studies
- NCT07183878Recruiting
Venetoclax with BUCY conditioning for high-risk AML or MDS transplant
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
Hangzhou, ZhejiangAges 12–60 - NCT07218510RecruitingPhase 2
Venetoclax, obinutuzumab, then epcoritamab for untreated CLL/SLL
This trial tests a new combination of three drugs for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment yet. The goal is to see if this approach helps control the disease with fewer side effects.
Duarte, CaliforniaAges 18 years+ - NCT07228273RecruitingPhase 2
A new drug combo for AML and high-risk MDS
This trial combines three standard chemotherapy drugs (fludarabine, cytarabine, idarubicin) with a targeted therapy (venetoclax) to treat acute myeloid leukemia (AML) and a related condition called MDS with high blast counts. The goal is to see if adding venetoclax improves results.
Portland, OregonAges 18–65 - NCT07231952RecruitingPhase 2
Pirtobrutinib, venetoclax, and rituximab for Waldenstrom's macroglobulinemia
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) for people newly diagnosed with Waldenstrom's macroglobulinemia who have not had treatment before and need therapy for their symptoms.
Boston, MassachusettsAges 18 years+ - NCT07238686RecruitingPhase 2
Venetoclax plus microtransplant for higher-risk MDS
This study tests a combination of venetoclax (a targeted drug) with a mini stem cell transplant (called a microtransplant) using a partially matched donor. It is for people with higher-risk MDS who cannot have a standard transplant.
BeijingAges 18 years+ - NCT07243483Recruiting
Studying venetoclax in untreated acute myeloid leukemia
This study looks at how the body processes venetoclax when it's given with azacitidine as a first treatment for acute myeloid leukemia (AML). It aims to understand how well the drug works and how the body handles it.
Bourgoin, FranceAges 18 years+ - NCT07244367Recruiting
Venetoclax maintenance for AML fit patients
This trial tests whether taking venetoclax can help keep your leukemia from coming back after you reach complete remission. It is for patients who are not able to get a bone marrow transplant right away.
SohagAges 18–60 - NCT07024706RecruitingPhase 2
Study of acalabrutinib plus venetoclax for relapsed CLL
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
Boston, MassachusettsAges 18–130 - NCT07254312Recruiting
Venetoclax blood levels and side effects in AML
This trial checks how the amount of venetoclax in your blood relates to side effects after you are in remission from AML. It aims to help doctors find the safest dose for you.
Pavia, PaviaAges Any age - NCT07294677RecruitingPhase 1/Phase 2
Study of capivasertib, venetoclax, and low-intensity chemo for ALL/LBL
This trial tests a combination of targeted drugs (capivasertib and venetoclax) with a gentle form of chemotherapy for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) that has come back or has not responded to previous treatment. The goal is to see if this approach is safe and effective.
Chicago, IllinoisAges 18 years+ - NCT07007052RecruitingPhase 2
Tagraxofusp plus venetoclax for newly diagnosed BPDCN
This trial tests a combination of two targeted drugs (tagraxofusp and venetoclax) for people with a rare blood cancer called BPDCN who have not been treated before. The goal is to see if this combination is safe and effective as a first treatment.
AmiensAges 18 years+ - NCT07374029RecruitingPhase 1
T cell therapy with vaccine, decitabine, and venetoclax in AML
This trial tests a treatment that combines a personalized vaccine made from your leukemia cells and your own immune cells (T cells) with standard chemotherapy drugs (decitabine and venetoclax). The goal is to help your immune system better fight the leukemia.
Boston, MassachusettsAges Any age - NCT07392242RecruitingPhase 2
Ivosidenib, azacitidine, and venetoclax for acute myeloid leukemia
This trial tests a combination of three targeted drugs for people with a specific type of AML that has an IDH1 mutation. The goal is to see if the combination helps control the leukemia and if continuing with just ivosidenib can keep it in remission.
Basking Ridge, New JerseyAges 60 years+ - NCT02115295RecruitingPhase 2
Venetoclax plus chemotherapy for AML, high-risk MDS, or blast CML
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
Houston, TexasAges 18–65 - NCT06357182RecruitingPhase 1
New drug combo for AML patients who can't have strong chemo
This trial tests a new drug combination (iadademstat plus azacitidine and venetoclax) for people with newly diagnosed AML who cannot have or do not want standard intensive chemotherapy. The goal is to see if adding iadademstat makes the treatment work better.
Portland, OregonAges 18 years+ - NCT07451912RecruitingPhase 1/Phase 2
Venetoclax Combo for CEBPA-Mutated AML in Unfit Patients
This trial tests a combination of three drugs (venetoclax, a hypomethylating agent, and low-dose cytarabine) for people with newly diagnosed AML that has a CEBPA gene mutation and who are not strong enough for standard intensive chemotherapy. The goal is to see if this gentler approach works well.
Suzhou, JiangsuAges 18 years+ - NCT07454226Recruiting
Drug combo for Ph-like acute lymphoblastic leukemia
This trial tests a combination of targeted drugs (ABL/JAK inhibitors) with chemotherapy and venetoclax for people with a type of leukemia called Ph-like ALL. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT07513129RecruitingPhase 1
New drug combination for relapsed T-cell blood cancer in teens and young adults
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
Houston, TexasAges 12–30 - NCT07514936RecruitingPhase 2
Venetoclax-Azacitidine With Chidamide and CAG for Older AML Patients
This trial tests a combination of four drugs (venetoclax, azacitidine, chidamide, and CAG chemotherapy) to treat newly diagnosed acute myeloid leukemia (AML—a blood cancer) in adults aged 60–75. The goal is to see if this combination helps patients live longer and feel better.
Beijing, None SelectedAges 60–75 - NCT07014462Enrolling by invitationPhase 1
Venetoclax and dexamethasone for untreated AML
This trial tests a combination of two oral medicines (venetoclax and dexamethasone) for people with newly diagnosed AML who cannot have or choose not to have high-dose chemotherapy. The goal is to see if this gentler treatment is safe and tolerable.
Burlington, VermontAges 18 years+ - NCT06697327Enrolling by invitation
Testing a three-drug combo for newly diagnosed AML
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
Hefei, AnhuiAges 18–59 - NCT06544109Enrolling by invitationPhase 2/Phase 3
Venetoclax to prevent differentiation syndrome in APL
This trial tests adding venetoclax to standard treatment to prevent a serious side effect called differentiation syndrome in people with newly diagnosed acute promyelocytic leukemia (APL). Patients must be healthy enough to receive intensive chemotherapy.
Suzhou, JiangsuAges Any age - NCT07131059Recruiting
Study for MRD-positive AML in remission
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT06265545Recruiting
Study for relapsed or hard-to-treat AML
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
TianjinAges Any age
Common questions
- Are there clinical trials studying Venetoclax?
- Yes. Clin2 currently lists 282 recruiting studies that include Venetoclax, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Venetoclax trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Venetoclax an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Venetoclax or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.